Boule Diagnostics AB Cash Flow Conversion Efficiency
Boule Diagnostics AB cash flow conversion efficiency. Based on the latest financial reports, Boule Diagnostics AB (BOUL) has a cash flow conversion efficiency ratio of -0.017x as of June 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (Skr-2.70 Million ≈ $-290.56K USD) by net assets (Skr161.50 Million ≈ $17.38 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Cash Flow Conversion Efficiency of Boule Diagnostics AB (2005–2024)
Cash flow conversion efficiency of Boule Diagnostics AB from 2005 to 2024. This chart illustrates how Boule Diagnostics AB's cash flow conversion efficiency has evolved over time, based on yearly financial data. View current stock price of Boule Diagnostics AB for real-time trading data and today's change.
Boule Diagnostics AB Cash Flow Conversion Ratio Explained
Boule Diagnostics AB cash flow conversion ratio divides operating cash flow by net assets, so a higher ratio means more cash generated from each unit of shareholder equity.
Boule Diagnostics AB Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Boule Diagnostics AB ranked by their cash flow conversion efficiency. Also see BOUL market cap for the company's overall valuation and market capitalisation.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Caledonia Mining Corporation Plc
LSE:CMCL
|
0.050x |
|
Qlife Holding AB
ST:QLIFE
|
-2.207x |
|
Maxeon Solar Technologies Ltd
NASDAQ:MAXN
|
0.148x |
|
Opawica Explorations Inc
V:OPW
|
-0.022x |
|
XORTX Therapeutics Inc
V:XRTX
|
-0.319x |
|
BELLUSCURA PLC LS -01
F:9VQ
|
N/A |
|
Sure-Tech Investments LP
TA:STEC
|
-0.038x |
|
Ibstock PLC
LSE:IBST
|
0.026x |
Annual Cash Flow Conversion Efficiency for Boule Diagnostics AB (2005–2024)
The table below shows the annual cash flow conversion efficiency of Boule Diagnostics AB from 2005 to 2024. Review Boule Diagnostics AB free cash flow efficiency to assess how much free cash flow the company generates relative to operating cash flow.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | Skr269.60 Million ≈ $29.01 Million |
Skr46.60 Million ≈ $5.01 Million |
0.173x | +59.84% |
| 2023-12-31 | Skr475.10 Million ≈ $51.13 Million |
Skr51.38 Million ≈ $5.53 Million |
0.108x | +540.55% |
| 2022-12-31 | Skr462.50 Million ≈ $49.77 Million |
Skr-11.35 Million ≈ $-1.22 Million |
-0.025x | -116.77% |
| 2021-12-31 | Skr295.74 Million ≈ $31.83 Million |
Skr43.28 Million ≈ $4.66 Million |
0.146x | -47.61% |
| 2020-12-31 | Skr269.30 Million ≈ $28.98 Million |
Skr75.24 Million ≈ $8.10 Million |
0.279x | +72.30% |
| 2019-12-31 | Skr332.87 Million ≈ $35.82 Million |
Skr53.98 Million ≈ $5.81 Million |
0.162x | +115.26% |
| 2018-12-31 | Skr300.86 Million ≈ $32.38 Million |
Skr22.66 Million ≈ $2.44 Million |
0.075x | -65.83% |
| 2017-12-31 | Skr261.77 Million ≈ $28.17 Million |
Skr57.72 Million ≈ $6.21 Million |
0.220x | +154.89% |
| 2016-12-31 | Skr229.76 Million ≈ $24.73 Million |
Skr19.88 Million ≈ $2.14 Million |
0.087x | -26.95% |
| 2015-12-31 | Skr188.51 Million ≈ $20.29 Million |
Skr22.32 Million ≈ $2.40 Million |
0.118x | -35.03% |
| 2014-12-31 | Skr169.99 Million ≈ $18.29 Million |
Skr30.98 Million ≈ $3.33 Million |
0.182x | +48.25% |
| 2013-12-31 | Skr127.49 Million ≈ $13.72 Million |
Skr15.68 Million ≈ $1.69 Million |
0.123x | +124.26% |
| 2012-12-31 | Skr199.69 Million ≈ $21.49 Million |
Skr10.95 Million ≈ $1.18 Million |
0.055x | +94.22% |
| 2011-12-31 | Skr192.86 Million ≈ $20.75 Million |
Skr5.44 Million ≈ $585.86K |
0.028x | -77.19% |
| 2010-12-31 | Skr130.56 Million ≈ $14.05 Million |
Skr16.16 Million ≈ $1.74 Million |
0.124x | +52.21% |
| 2009-12-31 | Skr100.89 Million ≈ $10.86 Million |
Skr8.20 Million ≈ $882.84K |
0.081x | +117.31% |
| 2008-12-31 | Skr115.22 Million ≈ $12.40 Million |
Skr4.31 Million ≈ $463.92K |
0.037x | -78.30% |
| 2005-12-31 | Skr132.36 Million ≈ $14.24 Million |
Skr22.82 Million ≈ $2.46 Million |
0.172x | -- |
About Boule Diagnostics AB
Boule Diagnostics AB (publ) develops, manufactures, and markets instruments and consumable products for blood diagnostics in the United States of America, Asia, Eastern Europe, Latin America, Western Europe, Africa, and the Middle East. The company provides hematology analyzers, reagents, controls, and calibrators, under the Swelab, Medonic, and Quintus brands; and veterinary hematology and clini… Read more